Published in BMC Cancer on October 28, 2016
Surfing the p53 network. Nature (2000) 35.36
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA (2013) 20.79
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L) Cell (1996) 10.83
The MAPK signaling cascade. FASEB J (1995) 10.81
RAS oncogenes: the first 30 years. Nat Rev Cancer (2003) 8.61
TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med (2007) 5.92
The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors (2006) 5.58
Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell (2011) 4.74
Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol (2008) 4.39
The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta (2006) 4.06
Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A (2009) 3.08
Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ (2008) 2.44
Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol (2008) 2.17
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol (2011) 2.03
HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988-2007). Ann Oncol (2008) 1.99
Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol (2010) 1.94
The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim Biophys Acta (2010) 1.85
The clinical development of MEK inhibitors. Nat Rev Clin Oncol (2014) 1.79
Identification and characterization of a general nuclear translocation signal in signaling proteins. Mol Cell (2008) 1.73
Nuclear translocation of mitogen-activated protein kinase kinase (MEK1) in response to mitogenic stimulation. Proc Natl Acad Sci U S A (1997) 1.72
The subcellular localization of MEK and ERK--a novel nuclear translocation signal (NTS) paves a way to the nucleus. Mol Cell Endocrinol (2009) 1.37
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer (2015) 1.27
p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer (2002) 1.02
Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway. Proc Natl Acad Sci U S A (2014) 0.99
MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer. BMC Cancer (2014) 0.88
Concurrent radiotherapy plus epidermal growth factor receptor inhibitors in patients with human papillomavirus-related head and neck cancer. Clin Transl Oncol (2013) 0.81
Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer. BMC Cancer (2013) 0.79